カテゴリ： GlobalData, アイルランド, 企業調査

Nabriva Therapeutics Plc (NBRV)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Nabriva Therapeutics Plc (NBRV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7606
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：76
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アイルランド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company’s product candidate includes lefamulin, a pleuromutilin antibiotic, being developed in both intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia. Its other pipeline products comprise BC-7013 for the topical treatment of a variety of gram-positive infections including uncomplicated skin and skin structure infections; and Contepo to treat urinary tract infections. It partners with pharmaceutical and biotechnology companies. It has operational presence in Austria and the US. Nabriva is headquartered in Dublin, Ireland.

Nabriva Therapeutics Plc (NBRV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Nabriva Therapeutics Raises USD120 Million in Series B Financing 11
Private Equity 13
Ally Bridge Invests in Nabriva Therapeutics 13
Licensing Agreements 14
Sinovant Sciences Enters into Licensing Agreement with Nabriva 14
Equity Offering 15
Nabriva Therapeutics Raises USD50 Million in Public Offering of Shares 15
Nabriva Therapeutics Raises USD80 Million in Public Offering of Shares 17
Nabriva Therapeutics Raises USD25 Million in Rights Offering of Shares 19
Nabriva Therapeutics Raises USD106.1 Million in IPO of ADS 21
Acquisition 23
Nabriva Therapeutics Acquires Zavante Therapeutics 23
Nabriva Therapeutics Plc – Key Competitors 24
Nabriva Therapeutics Plc – Key Employees 25
Nabriva Therapeutics Plc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 09, 2018: Nabriva Therapeutics reports second quarter 2018 financial results and recent corporate highlights 27
May 08, 2018: Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights 29
Mar 16, 2018: Nabriva Therapeutics Announces 2017 Financial Results 30
Nov 09, 2017: Nabriva Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights 32
Aug 07, 2017: Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights 34
May 10, 2017: Nabriva Therapeutics Reports First Quarter 2017 Financial Results 36
Mar 24, 2017: Nabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results 37
Corporate Communications 38
Mar 21, 2018: Nabriva Therapeutics Names Jennifer Schranz As Chief Medical Officer 38
Dec 13, 2017: Nabriva Therapeutics Added to NASDAQ Biotechnology Index 39
Aug 31, 2017: Nabriva Therapeutics Announces Resignation of Elyse Seltzer, M.D. 40
Jul 11, 2017: Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer 41
Jun 26, 2017: Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board 42
Product News 43
10/04/2017: Zavante Therapeutics Presents Additional Clinical And Microbiologic Data From ZOLYD Phase 2/3 Trial At ID Week 2017 43
09/28/2017: Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017 45
09/20/2017: Zavante Therapeutics To Present ZOLYD Data From Pivotal ZEUS Study At ID Week 2017 47
06/05/2017: Zavante Therapeutics Reports ZOLYD Broad Spectrum Activity and Synergy With Multiple Antibiotics; in vitro Studies Presented at ASM Microbe 2017 Meeting 49
04/05/2017: Zavante Therapeutics’ ZOLYD Met Primary Endpoint in Pivotal ZEUS Study for Treatment of Complicated Urinary Tract Infections 50
Clinical Trials 52
May 31, 2018: Nabriva Therapeutics to Present Lefamulin Data at ASM Microbe 52
May 29, 2018: Nabriva Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference 54
May 21, 2018: Nabriva Therapeutics Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia 55
May 21, 2018: Zavante Therapeutics to Present Fosfomycin For Injection Data At ASM Microbe 2018 Meeting 57
Apr 13, 2018: Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia 59
Dec 04, 2017: Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults 61
Oct 25, 2017: Nabriva Therapeutics to Present at the Stifel 2017 Healthcare Conference 62
Sep 20, 2017: Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference 63
Sep 18, 2017: Nabriva Therapeutics Announces Positive Topline Results from Global, Phase 3 Clinical Trial Evaluating IV and Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia 64
Jun 05, 2017: Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017 66
Jun 05, 2017: Zavante Therapeutics Presents Positive Results From NIH-Sponsored ZOLYD Phase 1 Trial At ASM Microbe 2017 Meeting 67
Jun 02, 2017: Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin 68
May 17, 2017: Zavante Therapeutics to Present ZOLYD Data at ASM Microbe 2017 Meeting 69
Apr 13, 2017: Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin 71
Apr 11, 2017: Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia 73
Feb 02, 2017: Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia 74
Jan 19, 2017: Zavante Therapeutics Reports Completion Of Patient Treatment In The ZEUS Study Of ZTI-01 (fosfomycin for injection) For The Treatment Of Complicated Urinary Tract Infections 75
Appendix 76
Methodology 76
About GlobalData 76
Contact Us 76
Disclaimer 76

List of Tables
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nabriva Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nabriva Therapeutics Raises USD120 Million in Series B Financing 11
Ally Bridge Invests in Nabriva Therapeutics 13
Sinovant Sciences Enters into Licensing Agreement with Nabriva 14
Nabriva Therapeutics Raises USD50 Million in Public Offering of Shares 15
Nabriva Therapeutics Raises USD80 Million in Public Offering of Shares 17
Nabriva Therapeutics Raises USD25 Million in Rights Offering of Shares 19
Nabriva Therapeutics Raises USD106.1 Million in IPO of ADS 21
Nabriva Therapeutics Acquires Zavante Therapeutics 23
Nabriva Therapeutics Plc, Key Competitors 24
Nabriva Therapeutics Plc, Key Employees 25
Nabriva Therapeutics Plc, Subsidiaries 26

List of Figures
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nabriva Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Nabriva Therapeutics Plc (NBRV)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Complexa Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Complexa Inc (Complexa) is a biopharmaceutical company that develops endogenous human cell signalling treatments for fibrosis and inflammation related diseases. The company’s lead product candidate products includes CXA-10 is an endogenous nitro fatty acid that modulates the human body’s mai …
  • African Development Bank Group：電力：M&Aディール及び事業提携情報
    Summary African Development Bank Group (AfDB) is a development finance institution. It promotes social and economic development by providing loans, grants, guarantees, equity investments and technical assistance in its regional member countries. The constituent institutions of the bank include The A …
  • TG Therapeutics Inc (TGTX)：企業の財務・戦略的SWOT分析
    TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Salvatore Ferragamo SpA (SFER)：企業の財務・戦略的SWOT分析
    Salvatore Ferragamo SpA (SFER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Babcock Power Inc：企業の戦略的SWOT分析
    Babcock Power Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Metalloinvest MC LLC：企業の戦略的SWOT分析
    Metalloinvest MC LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Gleason Research Associates Inc：企業の戦略的SWOT分析
    Gleason Research Associates Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Santen Pharmaceutical Co Ltd (4536)：医療機器：M&Aディール及び事業提携情報
    Summary Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacture and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for bacterial conjunctivitis, glaucoma, dry eye, Inflammation and others; OTC …
  • Pivotal Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Pivotal Therapeutics Inc (Pivotal Therapeutics) is a pharmaceutical company that develops and markets Omega-3 based therapies and therapeutic products for cardiovascular disorders. The company offers products such as VASCAZEN, a medical food formulated for the dietary management of an Omega- …
  • Simulations Plus Inc (SLP)：企業の財務・戦略的SWOT分析
    Simulations Plus Inc (SLP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Tzamal Medical Group Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Tzamal Medical Group Ltd (Tzamal Medical) is a medical device company that manufactures and markets medical equipment, implants, disposables, surgical instruments and veterinary drugs. The company’s products include disposable products, patient monitor equipment and patient self testing equi …
  • 3-D Matrix Inc：企業の戦略的SWOT分析
    3-D Matrix Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Yaskawa Electric Corp
    Yaskawa Electric Corp - Strategy, SWOT and Corporate Finance Report Summary Yaskawa Electric Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • FluoroPharma Medical Inc (FPMI)：企業の財務・戦略的SWOT分析
    Summary FluoroPharma Medical Inc (FluoroPharma) is a molecular imaging company that develops and commercialize proprietary medical diagnostic imaging products. The company develops breakthrough positron emission tomography imaging agents for the assessment and detection of acute and chronic forms of …
  • Qatar Holding LLC：企業のM&A・事業提携・投資動向
    Qatar Holding LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Qatar Holding LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Solvay Specialty Polymers Italy SpA：企業の戦略的SWOT分析
    Solvay Specialty Polymers Italy SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • UTStarcom Holdings Corp. (UTSI)：企業の財務・戦略的SWOT分析
    UTStarcom Holdings Corp. (UTSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Capital Properties Inc (CPTP)：企業の財務・戦略的SWOT分析
    Summary Capital Properties Inc (Capital Properties) is a real estate company that acquires, operates, develops, and manages real estate properties. The company's services include real estate management, investment, and development and petroleum storage operations with lease interests in downtown pro …
  • Australian Pharmaceutical Industries Ltd (API)：企業の財務・戦略的SWOT分析
    Australian Pharmaceutical Industries Ltd (API) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Rosenergoatom Concern JSC：企業の戦略的SWOT分析
    Rosenergoatom Concern JSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆